We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-0.88%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$227M
AUM Growth
-$15.9M
(-6.5%)
Cap. Flow
-$6.57M
Cap. Flow
% of AUM
-2.89%
Top 10 Holdings %
Top 10 Hldgs %
7.9%
Holding
407
New
8
Increased
60
Reduced
329
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
XFLT
XAI Floating Rate & Alternative Income Trust
XFLT
|
+$689K |
| 2 |
VTA
INVESCO DYNAMIC CREDIT OPPORTUNITIES FUND
VTA
|
+$551K |
| 3 |
BlackRock Floating Rate Income Strategies Fund
FRA
|
+$468K |
| 4 |
Enel Chile
ENIC
|
+$430K |
| 5 |
EFT
Eaton Vance Floating-Rate Income Trust
EFT
|
+$429K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GRA
W.R. Grace & Co.
GRA
|
+$1.73M |
| 2 |
BGX
Blackstone Long-Short Credit Income Fund
BGX
|
+$731K |
| 3 |
BGB
Blackstone Strategic Credit 2027 Term Fund
BGB
|
+$693K |
| 4 |
NOA
North American Construction
NOA
|
+$554K |
| 5 |
MCI
Barings Corporate Investors
MCI
|
+$524K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 25.28% |
| 2 | Real Estate | 19.7% |
| 3 | Energy | 13.28% |
| 4 | Utilities | 12% |
| 5 | Materials | 10.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Syndax Pharmaceuticals
SNDX
$1.71B
| $215K | 0.09% |
11,241
-594
| -5% | -$9.9K |
|
|
ESPR
252
DELISTED
Esperion Therapeutics
ESPR
| $214K | 0.09% |
17,773
-1,625
| -8% | -$23.7K |
|
253
MacroGenics
MGNX
$241M
| $214K | 0.09% |
10,213
-541
| -5% | -$13K |
|
|
RXDX
254
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $214K | 0.09% |
9,043
-476
| -5% | -$11.2K |
|
|
ETNB
255
DELISTED
89bio
ETNB
| $213K | 0.09% |
10,877
-565
| -5% | -$10.3K |
|
256
Lexicon Pharmaceuticals
LXRX
$1.04B
| $213K | 0.09% |
44,378
-2,321
| -5% | -$9.53K |
|
257
Novavax
NVAX
$1.21B
| $213K | 0.09% |
1,028
-49
| -5% | -$10.8K |
|
|
NBP
258
NovaBridge Biosciences American Depositary Shares
NBP
$195M
| $212K | 0.09% |
2,925
-161
| -5% | -$11.6K |
|
259
Precision BioSciences
DTIL
$182M
| $211K | 0.09% |
610
-32
| -5% | -$10.8K |
|
|
ITOS
260
DELISTED
iTeos Therapeutics
ITOS
| $209K | 0.09% |
7,731
-403
| -5% | -$10.5K |
|
261
Sutro Biopharma
STRO
$386M
| $209K | 0.09% |
1,107
-57
| -5% | -$10.8K |
|
262
Arvinas
ARVN
$528M
| $208K | 0.09% |
2,530
-125
| -5% | -$11K |
|
|
MRUS
263
DELISTED
Merus
MRUS
| $207K | 0.09% |
9,391
-485
| -5% | -$10.4K |
|
264
Curis
CRIS
$9.59M
| $206K | 0.09% |
66
-3
| -4% | -$9.37K |
|
265
Vir Biotechnology
VIR
$1.48B
| $203K | 0.09% |
4,664
-248
| -5% | -$10.7K |
|
|
GRCL
266
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
| $203K | 0.09% |
14,608
-755
| -5% | -$8.91K |
|
|
FMTX
267
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $203K | 0.09% |
8,759
-461
| -5% | -$10.9K |
|
|
RNAM
268
DELISTED
Avidity Biosciences
RNAM
| $202K | 0.09% |
8,189
-424
| -5% | -$9.22K |
|
269
Geron
GERN
$917M
| $201K | 0.09% |
146,618
-7,649
| -5% | -$10.2K |
|
|
KRTX
270
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $201K | 0.09% |
1,644
-84
| -5% | -$9.7K |
|
271
Immunocore
IMCR
$1.7B
| $199K | 0.09% |
5,359
-275
| -5% | -$9.28K |
|
272
Phathom Pharmaceuticals
PHAT
$940M
| $197K | 0.09% |
6,150
-326
| -5% | -$10.8K |
|
273
Prelude Therapeutics
PRLD
$368M
| $197K | 0.09% |
6,292
-330
| -5% | -$10.7K |
|
274
Cogent Biosciences
COGT
$6.83B
| $196K | 0.09% |
23,335
-1,219
| -5% | -$9.34K |
|
275
4D Molecular Therapeutics
FDMT
$507M
| $196K | 0.09% |
7,257
-385
| -5% | -$11K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
RC
Virtus ETF Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, Virtus ETF Advisers held 407 positions worth $227M, down 6.5% from $243M the previous quarter. Its ten largest holdings account for 7.9% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.4%. Virtus ETF Advisers opened 8 new positions and exited 10, leaving the 407-position portfolio largely intact.
By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 27% a quarter earlier, followed by Real Estate and Energy.
- Virtus ETF Advisers's largest Q3 2021 buy was XAI Floating Rate & Alternative Income Trust: 15,447 shares worth $663K.
- Virtus ETF Advisers added most to Enel Chile in Q3 2021, an estimated $430K increase.
- Virtus ETF Advisers's biggest Q3 2021 reduction was North American Construction, cutting an estimated $554K.
- Virtus ETF Advisers fully exited W.R. Grace & Co. in Q3 2021, selling an estimated $1.73M.
- Virtus ETF Advisers's ten largest holdings make up 7.9% of its $227M portfolio in Q3 2021.
- Virtus ETF Advisers opened 8 new positions and closed 10 in Q3 2021.
- Virtus ETF Advisers's portfolio value fell 6.5% quarter-over-quarter to $227M.
Based on Virtus ETF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.